Shares rose 11% during early leak of financial data from China's new drug industry

Newspaper reporters yesterday evening, the new drug industry Bulletin said, the company on September 22, 2013 received the China Securities Regulatory Commission Tianjin Certificate Supervision Bureau issued the "Administrative Supervision measures decision" (Jin-2013]9)　　Decision on the measures of issuing warning letter to Tianjin New drug Industry Group Co., Ltd. (hereinafter referred to as: Warning letter).　　The China Securities Regulatory Commission, the Tianjin Bureau, believes that the new drug industry in advance of the company's Web site disclosure of financial data, violated the letter of the provisions.　　The announcement showed that the Chinese new drug industry on August 15, 2013 in the SFC designated media issued 2013.5 Annual Bulletin, but the company earlier than July 18, 2013 in the company's Web site disclosed part of the financial data. China Securities Regulatory Commission in Tianjin, said that the above-mentioned acts of the new drug industry in violation of the "Listed Companies information disclosure management measures," the provisions of article 59th.　　It said that information disclosure obligations in the Company's Web site and other media to publish information not prior to the designated media, a press conference or a journalist should not substitute any form for the report or announcement obligation to be performed, instead of the interim reporting obligation to be performed in the form of periodic reports, and the management of information disclosure affairs should be strengthened.　　In this respect, the new drug industry said that the company will strengthen the relevant laws and regulations, the study of rules and regulations, further improve the internal control management construction, streamline the control process, the integration of information disclosure, media coverage, external information dissemination channels to prevent the recurrence of such incidents. According to the early disclosure of new drug industry data show that as of the end of June, the new drug industry to achieve the cumulative sales revenue of 54.4% of the Year, the summary report growth of 24.43%;　　17 major varieties of assessment to complete sales revenue accumulated 1.015 billion yuan, an increase of 11.76%, completed the annual task of 50.3%.　　A CPA told reporters that the company's early disclosure of data in the report, it may affect the shareholders of the company's future stock price judgments, thus affecting the company's share price. It is understood that July 18, 2013, the new drug industry shares on the day of 12.89 yuan/share, since then, the company's share price rose until August 15, the company disclosed the day before yesterday, the company's share price to suspend the rising trend.　　According to the reporter calculates, from July 18 to August 14, in less than one months time, the new drug industry share price from 12.89 yuan/shares rose to 14.33 yuan/share, rose up to 11.17%.　　The company's share price fell more than 10% in the three trading days after it reported a more than 40% per cent drop in net profit on August 15. Some investors pointed out that the company July 18 published in the official online data on a number of performance, far better than the data disclosed in the report, the company has published false data misleading consumers suspected. Investors who bought the new drug industry after July 18, said the publicDivision should compensate for investment losses.